Advantages of fast-acting ADP receptor blockade in ischemic heart disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 2, 2003, Pages 158-159

  Nurden, Alan T ^a   Nurden, Paquita ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE ANTAGONIST; ADENOSINE TRIPHOSPHATE DERIVATIVE; ANTICOAGULANT AGENT; AR C 69931 MX; CLOPIDOGREL; FIBRINOLYTIC AGENT; HEPARIN; PYRIDINE DERIVATIVE; RECEPTOR PROTEIN; RECEPTOR PROTEIN P2Y1; RECEPTOR PROTEIN P2Y12; THIENO[2,3 B]PYRIDINE DERIVATIVE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

BLEEDING; BLOOD CLOT LYSIS; BLOOD FLOW; CORONARY ARTERY DISEASE; DOG; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; THROMBOCYTE ADHESION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXICITY;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANIMALS; DRUG COMBINATIONS; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET ACTIVATION; PLATELET AGGREGATION; RECEPTORS, PURINERGIC P2; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037324281     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000053387.06709.32     Document Type: Editorial

References (20)

1. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86:222-232.
2. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new-congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 1992;80:2787-2796.
3. Nurden P, Savi, P, Heilmann, E, Bihour C, Herbert JM, Maffrand JP, Nurden AT. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. J Clin Invest. 1995;95:1612-1622.
4. Hollopeter G, Janrzen H-M, Vincent D, Li G, England L, Ramakrishnan V, Yang R-B, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409:202-207.
5. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1598.
6. 12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun. 2001;283:379-383.
7. 12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol. 2003;23: 357-362.
8. Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharm Exp Ther. 2000; 295:492-499.
9. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, Maliszewski CR. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest. 1997;99:1351-1360.
10. Becker RC. Platelet surface physiology and its importance in pharmacotherapy design and development: The adenosine diphosphate receptor antagonists. J Thromb Thrombolysis. 2000;10:35-53.
11. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777.
12. Storey RF, Oldroyd KG, Wilcox RG. Open multicenter study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001;85:401-407.
13. 12 in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol. 2002;22:686-691.
14. Humbert M, Nurden P, Bihour C, Pasquet J-M, Winckler J, Heilmann E, Savi P, Herbert J-M, Kunicki TJ, Nurden AT. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol. 1996;16:1532-1543.
15. Sakariessen KS, Örning L, Stormorken H. Role of ADP and thromboxanes in human thrombus formation in ex vivo models. Platelets. 1997;8:385-390.
16. 12) in platelet activation initiated by binding of von Willebrand factor to platelet GPIbα induced by conditions of high shear rate. Circulation. 2002;105:2531-2536.
17. 12 receptor. Br J Pharmacol. 2001;133:521-528.
18. 1 is required to inhibit platelet aggregation in whole blood under flow. Blood. 2001:98:3340-3345.
19. Léon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave J-P, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor-null mice. J Clin Invest. 1999;104:1731-1737.
20. Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol. 2002;22:364-373.